Caffeine Consumption in Glaucoma Patients and Healthy Subjects

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
Wills Eye
Study ID
NCT03675412
Status
Recruiting
Apply to this trial

Conditions

  • Glaucoma, Primary Open Angle

Eligibility Criteria

Sex
ALL
Age
18 Years - 90 Years
Healthy Volunteers
Accepted

Interventions

  • Caffeine tablet — DIETARY_SUPPLEMENT
    Each eligible participant will receive one 200 mg caffeine tablet to ingest after completing all baseline study tasks.

Study Details

Caffeine is the most widely consumed drinking nutrient in the world. Caffeine effects various organs and the vascular system. It decreases ocular blood flow due to vasoconstriction.

Key Dates

Start date
Dec 30, 2018
Status verified
Nov 2025
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
80 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC

Arms

  • Active Comparator: Glaucoma Patients
    Eligible participants include patients with mild, moderate or advanced primary open angle glaucoma (POAG) or primary angle closure glaucoma (PACG). Each participant will complete baseline study tasks. Each participant will then receive one 200 mg caffeine tablet to ingest. Study tasks will be performed 1 hour and 2 hours after caffeine ingestion.
  • Active Comparator: Healthy controls
    Eligible participants include healthy subjects with no eye diseases. Each participant will complete baseline study tasks. Each participant will then receive one 200 mg caffeine tablet to ingest. Study tasks will be performed 1 hour and 2 hours after caffeine ingestion.

Primary Outcome Measure

Blood flow change in back of eye before and after caffeine [ Time Frame: Baseline, Hour 1, Hour 2 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Wills Eye Glaucoma ServicePhiladelphiaPennsylvania19107
Jeanne Molineaux, COA
[email protected]
215-825-4713
Jonathan S Myers, MD (SUB_INVESTIGATOR)
Jay L Katz, MD (SUB_INVESTIGATOR)
Marlene R Moster, MD (SUB_INVESTIGATOR)
Michael J Pro, MD (SUB_INVESTIGATOR)
Scott Fudemberg, MD (SUB_INVESTIGATOR)
Anand Montravadi, MD (SUB_INVESTIGATOR)

Find similar trials in Philadelphia, PA

By research site
Wills Eye Glaucoma Service· Philadelphia, PA

Related Studies